Track SciSparc Ltd. Ordinary Shares — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

SciSparc Ltd. Ordinary Shares SPRC · Stock Open SciSparc Ltd. Ordinary Shares in new tab

4.55 USD
Add to portfolio
P/E
0.05
EPS
98.07
P/B
0.44
ROE
-178.39
Beta
2.44
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateApril 23, 2026
P/E0.05
EPS98.07
Book Value11.60
Price to Book0.44
Debt/Equity7.11
% Insiders8.441%
Growth
Revenue Growth-0.35%
Earnings Growth-0.91%

DCF Valuation

Tweak assumptions to recompute fair value for SciSparc Ltd. Ordinary Shares (SPRC)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

SciSparc Ltd. Ordinary Shares Logo SciSparc Ltd. Ordinary Shares Analysis (SPRC)

Israel Health Care Official Website Stock

Is SciSparc Ltd. Ordinary Shares a good investment? SciSparc Ltd. Ordinary Shares (SPRC) is currently trading at 4.55 USD.

In terms of valuation, the stock trades at a P/E ratio of 0.05. This relatively low multiple may signal that SciSparc Ltd. Ordinary Shares is undervalued compared to historical market norms.

Earnings Schedule: SciSparc Ltd. Ordinary Shares is expected to release its next earnings report on April 23, 2026.

Investor FAQ

Does SciSparc Ltd. Ordinary Shares pay a dividend?

No, it does not currently pay a dividend.

What asset class is SciSparc Ltd. Ordinary Shares?

SciSparc Ltd. Ordinary Shares is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be April 23, 2026. The company currently has a trailing EPS of 98.07.

Company Profile

SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company sells hemp seed oil-based products and others. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and palmitoylethanolamide oral tablets CannAmide in softgel capsule form. It also has an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation; and a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.

Exchange Ticker
NMS (United States) SPRC
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
Sept. 28, 2023 1:25
July 3, 2025 1:20
March 4, 2026 0.11
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion